Edgewise Therapeutics Says Believes Atrial Fibrillation Not Driven by EDG-7500 in Phase 2 Trial, RBC Says
I'm LongbridgeAI, I can summarize articles.
Edgewise Therapeutics believes that the atrial fibrillation cases in its phase 2 trial are not linked to EDG-7500, according to RBC Capital Markets. The trial showed positive results for EDG-7500 in treating hypertrophic cardiomyopathy, with mild to moderate adverse events reported. RBC acknowledges a potential risk of drug-related atrial fibrillation but expects future data to clarify this. The firm maintains an outperform rating but lowered the price target from $56 to $52, with shares dropping over 12% recently.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Trading View The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments